Both liraglutide and semaglutide have been shown to reduce obesity-induced muscle atrophy via a GLP-1/Sirtuin (SIRT1) pathway in rodents (40). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.